Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:activities |
inhibits viral RNA synthesis
|
| gptkbp:appointed_by |
oral tablet
inhalation solution |
| gptkbp:approves |
gptkb:1971
gptkb:FDA |
| gptkbp:brand |
gptkb:Copegus
gptkb:Rebetol Virazole |
| gptkbp:class |
nucleoside analog
|
| gptkbp:clinical_trial |
HCV treatment studies
RSV treatment studies |
| gptkbp:composed_of |
can be produced from ribose
synthesized from guanosine |
| gptkbp:contraindication |
pregnancy
severe renal impairment |
| gptkbp:developed_by |
ICN Pharmaceuticals
|
| gptkbp:formulation |
injection
oral capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Ribavirin
|
| gptkbp:ingredients |
C8 H11 N5 O5
|
| gptkbp:interacts_with |
gptkb:didanosine
gptkb:zidovudine gptkb:currency |
| gptkbp:is_used_for |
treatment of hepatitis C
treatment of respiratory syncytial virus (RSV) infection |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
excreted in urine
oral bioavailability 45% to 65% half Life 1.5 hours |
| gptkbp:research |
potential use in COVID-19
studies on Crimean-Congo hemorrhagic fever studies on Ebola virus studies on Lassa fever studies on viral hemorrhagic fevers |
| gptkbp:side_effect |
gptkb:historical_event
gptkb:fandom fatigue headache nausea rash insomnia thrombocytopenia |
| gptkbp:targets |
RNA viruses
|
| gptkbp:type_of |
36791-04-5
|